BOD Australia Ltd
ASX:BOD

Watchlist Manager
BOD Australia Ltd Logo
BOD Australia Ltd
ASX:BOD
Watchlist
Price: 0.024 AUD Market Closed
Market Cap: 4.3m AUD

Relative Value

BOD doesn't have a meaningful market cap.

The Relative Value of one BOD stock under the Base Case scenario is hidden AUD. Compared to the current market price of 0.024 AUD, BOD Australia Ltd is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

BOD Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
58
vs Industry
61
Median 3Y
2
Median 5Y
2.3
Industry
2.7
vs History
0
vs Industry
Median 3Y
-0.7
Median 5Y
-1.8
Industry
21.4
vs History
9
vs Industry
Median 3Y
-1.1
Median 5Y
-2.4
Industry
16.8
vs History
9
vs Industry
Median 3Y
-1
Median 5Y
-2.2
Industry
23.1
vs History
vs Industry
60
Median 3Y
-0.8
Median 5Y
2.3
Industry
2.3
vs History
55
vs Industry
92
Median 3Y
1.7
Median 5Y
2
Industry
2.9
vs History
42
vs Industry
89
Median 3Y
2.9
Median 5Y
3.6
Industry
5.5
vs History
9
vs Industry
Median 3Y
-0.8
Median 5Y
-1.1
Industry
13.3
vs History
9
vs Industry
Median 3Y
-0.8
Median 5Y
-1.1
Industry
16.5
vs History
9
vs Industry
Median 3Y
-1.3
Median 5Y
-1.5
Industry
16
vs History
9
vs Industry
Median 3Y
-1.3
Median 5Y
-1.5
Industry
18.9
vs History
vs Industry
80
Median 3Y
-1.3
Median 5Y
4.9
Industry
2

Multiples Across Competitors

BOD Competitors Multiples
BOD Australia Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
AU
BOD Australia Ltd
ASX:BOD
4.3m AUD 2 16.4 14.5 14.5
US
Eli Lilly and Co
NYSE:LLY
982.7B USD 16.5 53.3 35.8 38.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
528.3B USD 5.7 20.9 17.2 22.3
CH
Roche Holding AG
SIX:ROG
276B CHF 4.5 29.3 12.4 14.5
UK
AstraZeneca PLC
LSE:AZN
218.7B GBP 5 31.1 108.8 159.3
CH
Novartis AG
SIX:NOVN
220B CHF 4.9 19 12.1 15.6
US
Merck & Co Inc
NYSE:MRK
273.7B USD 4.2 14.2 10.2 12.1
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK 5.4 16.3 11.4 13.2
IE
Endo International PLC
LSE:0Y5F
213.9B USD 92.2 -73.2 338.7 849.2
US
Pfizer Inc
NYSE:PFE
146.1B USD 2.3 14.8 7.5 10.3
P/E Multiple
Earnings Growth PEG
AU
BOD Australia Ltd
ASX:BOD
Average P/E: 24
16.4
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
53.3
54%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
20.9
29%
0.7
CH
Roche Holding AG
SIX:ROG
29.3
29%
1
UK
AstraZeneca PLC
LSE:AZN
31.1
37%
0.8
CH
Novartis AG
SIX:NOVN
19
17%
1.1
US
Merck & Co Inc
NYSE:MRK
14.2
15%
0.9
DK
Novo Nordisk A/S
CSE:NOVO B
16.3
3%
5.4
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -73.2 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.8
27%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
AU
BOD Australia Ltd
ASX:BOD
Average EV/EBITDA: 401.3
14.5
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
35.8
34%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
17.2
9%
1.9
CH
Roche Holding AG
SIX:ROG
12.4
5%
2.5
UK
AstraZeneca PLC
LSE:AZN
108.8
10%
10.9
CH
Novartis AG
SIX:NOVN
12.1
6%
2
US
Merck & Co Inc
NYSE:MRK
10.2
6%
1.7
DK
Novo Nordisk A/S
CSE:NOVO B
11.4
1%
11.4
IE
E
Endo International PLC
LSE:0Y5F
338.7
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.5
0%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
AU
BOD Australia Ltd
ASX:BOD
Average EV/EBIT: 1 713.8
14.5
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
38.4
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
22.3
15%
1.5
CH
Roche Holding AG
SIX:ROG
14.5
6%
2.4
UK
AstraZeneca PLC
LSE:AZN
159.3
23%
6.9
CH
Novartis AG
SIX:NOVN
15.6
12%
1.3
US
Merck & Co Inc
NYSE:MRK
12.1
8%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
13.2
0%
N/A
IE
E
Endo International PLC
LSE:0Y5F
849.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.3
7%
1.5